

BAXTER INTERNATIONAL INC.
GAAP Key Product Line Sales
Periods Ending June 30, 2010 and 2009
(unaudited)
(\$ in millions)

	GAAP Q2 2010	GAAP Q2 2009	% Growth @ Actual Rates	% Growth @ Constant Rates	GAAP YTD 2010	GAAP YTD 2009	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$525	\$515	2%	1%	\$1,035	\$966	7%	4%
Plasma Proteins	314	353	(11%)	(12%)	606	627	(3%)	(8%)
Antibody Therapy	310	344	(10%)	(10%)	632	681	(7%)	(8%)
Regenerative Medicine	133	109	22%	21%	252	208	21%	18%
Other ¹	76	97	(22%)	(22%)	195	188	4%	(2%)
Total BioScience	\$1,358	\$1,418	(4%)	(5%)	\$2,720	\$2,670	2%	(1%)
Medication Delivery								
IV Therapies	\$418	\$384	9%	4%	\$809	\$728	11%	5%
Global Injectables	472	418	13%	10%	923	789	17%	12%
Infusion Systems ²	216	205	5%	2%	212	404	(48%)	(52%)
Anesthesia	130	120	8%	6%	257	229	12%	8%
Other	3	7	(57%)	(57%)	7	19	(63%)	(53%)
Total Medication Delivery²	\$1,239	\$1,134	9%	6%	\$2,208	\$2,169	2%	(3%)
Renal								
PD Therapy	\$480	\$454	6%	0%	\$954	\$874	9%	2%
HD Therapy	105	96	9%	5%	215	191	13%	5%
Total Renal	\$585	\$550	6%	1%	\$1,169	\$1,065	10%	3%
Transfusion Therapies³	\$12	\$21	(43%)	(43%)	\$24	\$43	(44%)	(44%)
Total Baxter²	\$3,194	\$3,123	2%	0%	\$6,121	\$5,947	3%	(1%)

¹ Principally includes vaccines and sales of plasma to third parties.

² GAAP net sales in the first quarter of 2010 included a charge of \$213 million related to the recall of COLLEAGUE infusion pumps from the U.S. market. Refer to page 16 for a reconciliation to GAAP measures.

³ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.